Bevacizumab Biosimilar, N297A Mutant | Catalog C001P.NA

Bevacizumab Biosimilar, N297A Mutant. Bevacizumab biosimilar CHO stable cell line is available for licensing to manufacture the bevacizumab biosimilar protein. The research grade bevacizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available.

Product Specifications

Catalog No.	C001P.NA
Product Name	Bevacizumab Biosimilar, N297A Mutant
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Anti-VEGF-A Humanized Monoclonal Antibody
Summary	Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.
Source/Host	Produced in the bevacizumab biosimilar CHO stable cell line.
Specificity	Specifically binds to human VEGF-A.

Properties & Storage

Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab.
Formulation	0.2 µM filtered solution, pH 6.2, no stabilizers or preservatives.
Endotoxin	< 0.1 EU per 1 µg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.

Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.